ALK and neoplasm: The fact that the more commonly occurring crizotinib-resistant ALK mutations (i.e., L1196 M and G1269A) were not observed in ceritinib-resistant samples, suggesting that different patterns of resistance will emerge depending on the selective pressure of the individual ALK inhibitors for deriving resistant tumor subclones.